 |
(Photo= Yonhap news) |
[Alpha Biz= Reporter Kim Jisun] Celltrion Group has seen declines in the stock prices of both Celltrion and Celltrion Pharm due to ongoing discussions about a potential merger between the two companies.
According to the Korea Exchange on the 4th, Celltrion's stock closed at 193,600 KRW, down 3.2% (6,400 KRW) from the previous week. Celltrion Pharm also fell 8.9% (8,200 KRW) to 83,800 KRW.
Recently, Celltrion Group announced the establishment of a 'Merger Review Phase 1 Special Committee' composed entirely of outside directors from both companies to evaluate the feasibility of a merger between Celltrion and Celltrion Pharm. The companies also plan to conduct a survey of shareholders regarding the merger. The special committee will submit its final opinion to the boards of directors based on the survey results, synergy evaluations, and assessments from external neutral institutions. If the merger is deemed feasible, a 'Phase 2 Special Committee' will be formed to proceed with the formal merger process.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
